Comparative Pharmacology
Head-to-head clinical analysis: HICON versus TIOTROPIUM BROMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HICON versus TIOTROPIUM BROMIDE.
HICON vs TIOTROPIUM BROMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Unknown; possibly involves modulation of hypothalamic thermoregulatory center.
Tiotropium bromide is a long-acting, competitive, and reversible muscarinic receptor antagonist (anticholinergic). It binds preferentially to M3 receptors in the smooth muscle of the bronchi, inhibiting acetylcholine-mediated bronchoconstriction and mucus secretion, leading to prolonged bronchodilation.
HICON (norepinephrine) 0.05-0.5 mcg/kg/min IV continuous infusion, titrated to blood pressure.
Inhalation (oral): 18 mcg once daily via HandiHaler; or 2.5 mcg (2 puffs) once daily via Respimat inhaler.
None Documented
None Documented
Terminal half-life: 12-18 hours; prolonged to 24-36 hours in renal impairment (CrCl <30 mL/min)
Terminal elimination half-life: 5–6 days (inhalation). Longer half-life allows once-daily dosing. Steady-state reached in 2–3 weeks.
Renal: 70% as unchanged drug; biliary/fecal: 25% as metabolites; 5% other
Primarily renal: 14% of dose excreted unchanged in urine; remainder as inactive metabolites via biliary/fecal (70%) and renal (30% total).
Category C
Category A/B
Anticholinergic
Anticholinergic